Female Genital Schistosomiasis (FGS) in a Nonendemic Setting: Retrospective Case-Notes Review of -Positive FGS Cases at the Hospital for Tropical Diseases, London, With a Pragmatic Clinical Pathway for Nonendemic Settings.

BACKGROUND

Female genital schistosomiasis (FGS), the genital manifestation of infection in women, results in protean gynecological symptoms and longer-term complications. FGS affects an estimated 75% of women with , totaling 56 million women, mainly in Sub-Saharan Africa. With increasing migration, FGS will be encountered more frequently in nonendemic settings. Despite this, evaluation of FGS diagnosis and management and guidelines for these settings are lacking.

METHODS

A retrospective case-notes review was undertaken of patients presenting to the Hospital for Tropical Diseases, London, from 1998 to 2018 with ova in terminal urine or on biopsy. Descriptive and outcome variables were collected. Specific FGS variables included documented gynecological symptoms and referrals to sexual health and gynecology specialists. Results informed a clinical pathway aiding diagnosis and management of FGS.

RESULTS

Overall, 186 patients with ova in terminal urine or biopsy were included, 62 (33.3%) of whom were women. Four women had documented gynecological symptoms (4/62, 6.5%). Two symptomatic women were referred to gynecology (2/4, 50%), and 2 were lost to follow-up (2/4, 50%). Gynecological symptoms were not documented for many women, despite proven infection.

CONCLUSIONS

Given that 75% of women with infection may have FGS, there is a gap in diagnosis in this nonendemic setting. We developed a clinical pathway to improve diagnosis and management of FGS, including inquiry about gynecological symptoms, followed by targeted referrals to gynecology, sexual health, and urological imaging. By formalizing a pathway, we aim to improve FGS care in this nonendemic setting.